Accomplishment of tenth milestone triggers EUR 2.5 million payment from Boehringer Ingelheim to Evotec Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone, triggering a payment of EUR 2.5 million to Evotec. The milestone reached was selecting an applicant compound for pre-development research in an swelling and immunology programme. Dr. Werner Lanthaler, CEO of Evotec, commented: This is the tenth milestone achieved since the inception of the collaboration between Boehringer Ingelheim and Evotec in 2004, therefore underlining the great success of 1 of the largest and most significant global research alliances between pharma and biotech.Pituitary tumors also can damagethe pituitary gland itself, disrupting hormone production. The resulting hormone imbalances are responsible for symptoms such as for example impotence, low sex drive, and changes in the menstrual period. Symptoms because of excess growth hormone or IGF-I vary widely. These do not take place in everyone with acromegaly. Irritability Exhaustion Fainting Weakness Improved thirst or urination Shortness of breath Chest pain Palpitations or rapid heart beat Poor exercise tolerance.
Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research Advanced Life Sciences Holdings, Inc. , a biopharmaceutical organization engaged in the discovery, commercialization and development of novel medications in the therapeutic regions of infection, oncology and respiratory diseases, today announced that it offers entered into a Cooperative Research and Development Contract with The Walter Reed Army Institute of Study.